Pharma Pulse 7/22/24: J.D. Vance’s AI Agenda, Fighting the Flu With Supplements & more

Enhancing Care and Research: Digital Technology's Impact on Rett Syndrome Management

Wearables have great potential to continue advancing research in Rett syndrome as well as other rare disease areas.

Fighting the Flu With Supplements: The Pharmacist’s Patient Counseling Guide

Confusing product labeling and conflicting data can create challenges for patients.

J.D. Vance’s A.I. Agenda: Reduce Regulation

Donald Trump’s vice-presidential pick has indicated he favors a hands-off approach to A.I. but also wants to increase scrutiny of the biggest tech firms in the field.

Global Diabetes and Obesity Therapeutics, 2024 2028: Lucrative Market Opportunities with GLP-1-based Multi-agonists with Improved Tolerability Profile - ResearchAndMarkets.com

The "Growth Opportunities in Global Diabetes and Obesity Therapeutics, 2024 2028" report has been added to ResearchAndMarkets.com's offering.

This study aims to identify the primary growth opportunities that will drive the diabesity market in the near future. The study also aims to highlight the most prominent and emerging business models prevalent across the market that will enable industry stakeholders to enhance their geographic coverage in terms of patient outreach and address the challenges of limited patient access.

Avalere Health on LinkedIn

Avalere Health CEO Jon Koch attended ISPOR—The Professional Society for Health Economics and Outcomes Research 2024 to hear how life sciences and medical device companies are approaching whole-person health – an all-encompassing way of understanding the patient’s entire lived experience. Learn how effective and holistic data integration can make this a reality in Jon’s article withPharmaceutical Executive: https://bit.ly/3S3FwHF

#WeAreAvalereHealth #AvalereHealth #MarketAccess #HealthCareMarketing

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs